



# Source details

## Pathophysiology

Open Access ⓘ

Scopus coverage years: from 1994 to Present

Publisher: Multidisciplinary Digital Publishing Institute (MDPI)

ISSN: 0928-4680 E-ISSN: 1873-149X

Subject area: Medicine: Pathology and Forensic Medicine Medicine: Physiology (medical)

Source type: Journal

CiteScore 2022

2.8 ⓘ

SJR 2022

0.369 ⓘ

SNIP 2022

0.655 ⓘ

[View all documents >](#)

[Set document alert](#)

[Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

### i Improved CiteScore methodology

CiteScore 2022 counts the citations received in 2019-2022 to articles, reviews, conference papers, book chapters and data papers published in 2019-2022, and divides this by the number of publications published in 2019-2022. [Learn more >](#)

CiteScore 2022 ▼

$$2.8 = \frac{366 \text{ Citations 2019 - 2022}}{132 \text{ Documents 2019 - 2022}}$$

Calculated on 05 May, 2023

CiteScoreTracker 2023 ⓘ

$$3.0 = \frac{361 \text{ Citations to date}}{120 \text{ Documents to date}}$$

Last updated on 08 November, 2023 • Updated monthly

### CiteScore rank 2022 ⓘ

Category	Rank	Percentile
Medicine		
└ Pathology and Forensic Medicine	#91/193	53rd
Medicine		
└ Physiology (medical)	#69/102	32nd



[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)

SJR Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name


Home Journal Rankings Country Rankings Viz Tools Help About Us

## Pathophysiology

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
<p>Switzerland</p> <p> Universities and research institutions in Switzerland</p> <p> Media Ranking in Switzerland</p>	<p>Medicine</p> <ul style="list-style-type: none"> <li>Pathology and Forensic Medicine</li> <li>Physiology (medical)</li> </ul>	<p>Multidisciplinary Digital Publishing Institute (MDPI)</p>	<p><b>56</b></p>
PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
<p>Journals</p>	<p>09284680, 1873149X</p>	<p>1994-2022</p>	<p><a href="#">Homepage</a></p> <p><a href="#">How to publish in this journal</a></p> <p><a href="mailto:pathophysiology@mdpi.com">pathophysiology@mdpi.com</a></p>

### SCOPE


Pathophysiology (ISSN 1873-149X) is an international, peer-reviewed open access journal which provides an advanced forum for studies related the etiology, development, and elimination of pathological processes. Contributions on the basic mechanisms underlying these processes, model systems and interdisciplinary approaches are strongly encouraged. An international editorial board welcomes contributions covering the following areas: -General pathophysiological processes: inflammation, infection, hypoxia, stress, shock, pain, dysregulation- Cellular and molecular pathophysiology- Neuroscience- Heart and circulation- Respiratory system- Renal, fluid and electrolyte pathophysiology- Gastrointestinal and hepatic system- Endocrine system- Metabolic disorders- Blood system- Immune system- Reproductive system- Locomotor system

 Join the conversation about this journal

Quartiles

**FIND SIMILAR JOURNALS**

<p>1</p> <p>Life Sciences</p> <p>USA</p> <p><b>64%</b></p>	<p>2</p> <p>Archives of Physiology and Biochemistry</p> <p>GBR</p> <p><b>63%</b></p>	<p>3</p> <p>Clinical and Experimental Pharmacology and</p> <p>GBR</p> <p><b>61%</b></p>	<p>4</p> <p>Pharmacological Research</p> <p>USA</p> <p><b>60%</b></p>	<p>5</p> <p>Journal of Basic and Clinical Physiology and</p> <p>DEU</p> <p><b>60%</b></p>
--	--	---	---	---



Metrics based on Scopus® data as of April 2023

**Leave a comment**

Name

Email   
(will not be published)

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.





An official website of the United States government

[Here's how you know](#) ▾

Filter your results: All (160)

National Library of Medicine  
National Center for Biotechnology Information

Log in

PMC ▾

"Pathophysiology"[journal] ✕

Display Settings: ▾ Summary, 20 per page, Sorted by Default order

You searched **8+ million full text articles**Try this search in **34+ million citations and abstracts** ↗

## PMC Full-Text Search Results

Items: 81 to 100 of 160

- [Sex Differences in Immune Cell Infiltration and Hematuria in SCI-Induced Hemorrhagic Cystitis](#)  
81. Hadi Askarifirouzjaei, Leila Khajoueinejad, Elena Wei, Sruti Cheruvu, Carlos Ayala, Ning Chiang, Thomas Theis, Dongming Sun, Mehdi Fazeli, Wise Young  
**Pathophysiology**. 2023 Sep; 30(3): 275–295. Published online 2023 Jul 11. doi: 10.3390/pathophysiology30030023  
PMCID: PMC10366728
- [Myocardial Glutathione Synthase and TRXIP Expression Are Significantly Elevated in Hypertension and Diabetes: Influence of Stress on Antioxidant Pathways](#)  
82. Anastasia Sklifasovskaya, Mikhail Blagonravov, Madina Azova, Vyacheslav Goryachev  
**Pathophysiology**. 2023 Jun; 30(2): 248–259. Published online 2023 Jun 12. doi: 10.3390/pathophysiology30020021  
PMCID: PMC10302676
- [Duration of SARS-CoV-2 RNA Shedding Is Significantly Influenced by Disease Severity, Bilateral Pulmonary Infiltrates, Antibiotic Treatment, and Diabetic Status: Consideration for Isolation Period](#)  
83. Muhammad Vitanata Arfijanto, Tri Pudy Asmarawati, Bramantono Bramantono, Musofa Rusli, Brian Eka Rachman, Bagus Aulia Mahdi, Nasronudin Nasronudin, Usman Hadi  
**Pathophysiology**. 2023 Jun; 30(2): 186–198. Published online 2023 May 4. doi: 10.3390/pathophysiology30020016  
PMCID: PMC10204499
- [Advantages of Multiposition Scanning in Echocardiographic Assessment of the Severity of Discordant Aortic Stenosis](#)  
84. Elena Zelikovna Golukhova, Inessa Viktorovna Slivneva, Inga Yur'evna Farulova, Ivan Ivanovich Skopin, Damir Ildarovich Marapov, Dar'ya Vladimirovna Murysova, Yuliya Dmitrievna Pirushkina, Irina Vasilyevna Volkovskaya  
**Pathophysiology**. 2023 Jun; 30(2): 174–185. Published online 2023 Apr 26. doi: 10.3390/pathophysiology30020015  
PMCID: PMC10204481
- [Risk Factors and Clinical Characteristics of Acute Kidney Injury in Patients with COVID-19: A Systematic Review and Meta-Analysis](#)  
85. Amal Arifi Hidayat, Vania Azalia Gunawan, Firda Rachmawati Iragama, Rizky Alfiansyah, Decsa Medika

Hertanto, Artaria Tjempakasari, Mochammad Thaha

**Pathophysiology.** 2023 Jun; 30(2): 233–247. Published online 2023 May 15. doi: 10.3390/pathophysiology30020020

PMCID: PMC10204466

86. [Retrospective Analysis of Real-World Data for the Treatment of Obstructive Sleep Apnea with Slow Maxillary Expansion Using a Unique Expansion Dental Appliance \(DNA\)](#)  
Nhi Dao, Colette Cozean, Oleg Chernyshev, Clete Kushida, Jonathan Greenburg, Jonathan S. Alexander  
**Pathophysiology.** 2023 Jun; 30(2): 199–208. Published online 2023 May 9. doi: 10.3390/pathophysiology30020017  
PMCID: PMC10204354
87. [Hormone Replacement Therapy Does Not Eliminate Risk Factors for Joint Complications following Total Joint Arthroplasty: A Matched Cohort Study](#)  
Lacee K. Collins, Matthew W. Cole, Timothy L. Waters, Michael Iloanya, Patrick A. Massey, William F. Sherman  
**Pathophysiology.** 2023 Jun; 30(2): 123–135. Published online 2023 Apr 4. doi: 10.3390/pathophysiology30020011  
PMCID: PMC10123744
88. [Neurotrophin-3 \(NT-3\) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer Treatment](#)  
Samvel Tonyan, Maria Pospelova, Varvara Krasnikova, Olga Fionik, Tatyana Alekseeva, Konstantin Samochnykh, Nataliya Ivanova, Tatyana Vavilova, Elena Vasilieva, Albina Makhanova, Aleksandra Nikolaeva, Tatyana Bukkieva, Stephanie Combs, Maxim Shevtsov  
**Pathophysiology.** 2023 Jun; 30(2): 110–122. Published online 2023 Apr 3. doi: 10.3390/pathophysiology30020010  
PMCID: PMC10123681
89. [Random Blood Glucose, but Not HbA1c, Was Associated with Mortality in COVID-19 Patients with Type 2 Diabetes Mellitus—A Retrospective Study](#)  
Stefanus Gunawan Kandinata, Soebagijo Adi Soelistijo, Agung Pranoto, Erwin Astha Triyono  
**Pathophysiology.** 2023 Jun; 30(2): 136–143. Published online 2023 Apr 6. doi: 10.3390/pathophysiology30020012  
PMCID: PMC10123645
90. [Shock-Associated Systemic Inflammation in Amniotic Fluid Embolism, Complicated by Clinical Death](#)  
Anatoly Brazhnikov, Natalya Zotova, Liliya Solomatina, Alexey Sarapultsev, Alexey Spirin, Evgeni Gusev  
**Pathophysiology.** 2023 Mar; 30(1): 48–62. Published online 2023 Feb 21. doi: 10.3390/pathophysiology30010006  
PMCID: PMC10058189
91. [The Emerging Role of Heat Shock Factor 1 \(HSF1\) and Heat Shock Proteins \(HSPs\) in Ferroptosis](#)  
Iman Aolymat, Ma'mon M. Hatmal, Amin N. Olaimat  
**Pathophysiology.** 2023 Mar; 30(1): 63–82. Published online 2023 Mar 14. doi: 10.3390/pathophysiology30010007  
PMCID: PMC10057451
92. [Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A Systematic Review of the Literature](#)  
Alice Ordean, Meara Tubman-Broeren  
**Pathophysiology.** 2023 Mar; 30(1): 27–36. Published online 2023 Feb 11. doi: 10.3390/pathophysiology30010004  
PMCID: PMC9944489
93. [Dietary Supplementation with Resveratrol Attenuates Serum Melatonin Level, Pro-Inflammatory Response and Metabolic Disorder in Rats Fed High-Fructose High-Lipid Diet under Round-the-Clock Lighting](#)  
Yurii Frenkel, Valerii Chernov, Heorhii Kostenko, Hitesh Chopra, Rupesh K. Gautam, Vitalii Kostenko  
**Pathophysiology.** 2023 Mar; 30(1): 37–47. Published online 2023 Feb 19. doi: 10.3390/pathophysiology30010005  
PMCID: PMC9944068



[Journals \(/about/journals\)](#)

[Topics \(/topics\)](#)

[Information \(/authors\)](#)

[Author Services \(/authors/english\)](#)

[Initiatives \(/about/initiatives\)](#)

[About](#)

[\(/about\)](#)

[Sign In / Sign Up \(/user/login\)](#)

[Submit \(https://susy.mdpi.com/user/manuscripts/upload?journal=pathophysiology\)](https://susy.mdpi.com/user/manuscripts/upload?journal=pathophysiology)

**Search for Articles:**

**Advanced Search**

[Journals \(/about/journals\)](#) / [Pathophysiology \(/journal/pathophysiology\)](#) / [Editorial Board](#)



**Journal Menu**

- [Pathophysiology Home \(/journal/pathophysiology\)](#)
- [Aims & Scope \(/journal/pathophysiology/about\)](#)
- [Editorial Board \(/journal/pathophysiology/editors\)](#)
- [Instructions for Authors \(/journal/pathophysiology/instructions\)](#)
- [Special Issues \(/journal/pathophysiology/special\\_issues\)](#)
- [Topics \(/topics?journal=pathophysiology\)](#)
- [Topical Collections \(/journal/pathophysiology/topical\\_collections\)](#)
- [Article Processing Charge \(/journal/pathophysiology/apc\)](#)
- [Indexing & Archiving \(/journal/pathophysiology/indexing\)](#)
- [Most Cited & Viewed \(/journal/pathophysiology/most\\_cited\)](#)
- [Journal Statistics \(/journal/pathophysiology/stats\)](#)
- [Journal History \(/journal/pathophysiology/history\)](#)
- [Society Collaborations \(/journal/pathophysiology/societies\)](#)
- [Editorial Office \(/journal/pathophysiology/editorial\\_office\)](#)

**Journal Browser**

**Journal Browser**

- > [Forthcoming issue \(/1873-149X/30/4\)](#)
- > [Current issue \(/1873-149X/30/3\)](#)

- [Vol. 30 \(2023\) \(/1873-149X/30\)](#)
- [Vol. 29 \(2022\) \(/1873-149X/29\)](#)
- [Vol. 28 \(2021\) \(/1873-149X/28\)](#)
- [Vol. 27 \(2020\) \(/1873-149X/27\)](#)

**Volumes not published by MDPI**

[Vol. 1-26 \(1994-2019\) \(https://www.sciencedirect.com/journal/pathophysiology\)](https://www.sciencedirect.com/journal/pathophysiology)



# Editorial Board

Please note that the order in which the Editors appear on this page is alphabetical, and follows the structure of the editorial board presented on the MDPI website under information for editors: [editorial board responsibilities \(editors#Editorial Board Responsibilities\)](#).

## Members

Search by first name, last name, affiliation, int



**Jonathan Steven Alexander** ([https://sciprofiles.com/profile/64757?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/64757?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://www.lsuhs.edu/departments/school-of-graduate-studies/molecular-and-cellular-physiology/research/alexander-lab>)

*Editor-in-Chief*

LSU Health Sciences Center-Shreveport, Shreveport, LA, USA

**Interests:** neurophysiology; neurodegeneration; cellular neuroscience; neurobiology; stroke therapy; kidney and liver transplantation; 3D tissue engineering

[Special Issues, Collections and Topics in MDPI journals](#)



**Farida Ahangari** ([https://sciprofiles.com/profile/2872245?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/2872245?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://medicine.yale.edu/intmed/pulmonary/profile/farida-ahangari/?tab=research>)

*Editorial Board Member*

Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA

**Interests:** metabolic reprogramming; chronic lung diseases; pulmonary fibrosis; lung inflammation; asthma



**Silvia M. Arribas** ([https://sciprofiles.com/profile/530056?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/530056?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://www.researchgate.net/profile/Silvia-Arribas-4> [Website2 \(https://foschgroup.github.io/\)](https://foschgroup.github.io/)

*Editorial Board Member*

Department of Physiology, Faculty of Medicine, Universidad Autonoma de Madrid, C/ Arzobispo Morcillo 2, 28029-Madrid, Spain

**Interests:** fetal programming; hypertension; oxidative stress biomarkers; nutrition; confocal microscopy

[Special Issues, Collections and Topics in MDPI journals](#)



**Nicolás G. Bazán** ([https://sciprofiles.com/profile/1551862?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/1551862?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
[https://www.medschool.lsuhs.edu/neuroscience/faculty\\_detail.aspx?name=bazan\\_nicolas](https://www.medschool.lsuhs.edu/neuroscience/faculty_detail.aspx?name=bazan_nicolas))

*Editorial Board Member*

LSUHSC Neuroscience Center, New Orleans, LA, USA

**Interests:** neuroprotection and neural/synaptic plasticity; unraveling cell survival signaling in injury and neurodegeneration; stroke; epilepsy; Alzheimer's disease; retinal degenerations; inflammatory response and resolution; omega-3 fatty acids; memory formation; cell signaling for successful aging



**Maria Bloksgaard** ([https://sciprofiles.com/profile/117183?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/117183?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<http://www.dambic.dk/index.php?page=Maria-Bloksgaard>)

*Editorial Board Member*

The Research Unit of Cardiovascular and Renal Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark

**Interests:** resistance artery mechanics and pharmacology; endothelial function and dysfunction; smooth muscle phenotype; fluorescence microscopy; wire myography; pressure myography; hypertension; diabetes; oxidative stress



**Omar Cauli** ([https://sciprofiles.com/profile/89020?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/89020?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://www.uv.es/uvweb/departamento-enfermeria/es/investigacion/grupos-investigacion/-frailty-research-organized-group-/miembros-del-grupo-1285857900444.html>)

*Editorial Board Member*

Department of Nursing, University of Valencia, 46010 Valencia, Spain

**Interests:** cognitive impairment; frailty syndrome; neurodevelopmental disorders; depression; neuropathy; sleep; environmental factors; comorbidity; immune alterations; metabolic alterations; biomarkers

[Special Issues, Collections and Topics in MDPI journals](#)



**Giulia Martina Cavestro** ([https://sciprofiles.com/profile/1147287?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/1147287?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://www.hsr.it/dottori/giulia-martina-cavestro>)

*Editorial Board Member*

Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, Italy

**Interests:** gastrointestinal hereditary tumors; Lynch syndrome; familial adenomatous polyposis; Peutz Jeghers syndrome; hereditary pancreatic cancer; familial pancreatic cancer; familial diffuse gastric cancer; serrated polyposis

[Special Issues, Collections and Topics in MDPI journals](#)

**Dr. Martina Cebova** ([https://sciprofiles.com/profile/88349?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/88349?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))

[Website \(https://www.sav.sk/?lang=sk&doc=user-org-user&user\\_no=4108\)](https://www.sav.sk/?lang=sk&doc=user-org-user&user_no=4108)

*Editorial Board Member*

Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Sienkiewiczova 1, 813 71 Bratislava, Slovakia




**Interests:** myocardial infarction; heart failure; obesity; gasotransmitters; morphological analysis




**Gediminas Cepinskas**  
<https://www.lawsonresearch.ca/scientist/dr-gediminas-cepinskas>)

**Editorial Board Member**

1. Lawson Health Research Institute, London, ON N6C 2R5, Canada
2. Department of Medical Biophysics, Western University, London, ON N6A 3K7, Canada
3. Department of Anatomy & Cell Biology, Western University, London, ON N6A 3K7, Canada

 [\(toggle desktop layout cookie\)](#)  


**Interests:** systemic inflammation/sepsis; ischemia/reperfusion; endothelial cell-leukocyte interaction; proteases/proteolytic injury; gaseous transmitters (CO, NO, H<sub>2</sub>S)

 **Hsuei-Chen Chen** ([https://sciprofiles.com/profile/2052653?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/2052653?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<http://www.ohri.ca/profile/hchenlab/profile>)

**Editorial Board Member**

Ottawa Hospital Research Institute, University of Ottawa, Neuroscience, Ottawa, ON, Canada


**Interests:** neural/synaptic plasticity; neuroinflammation; neural control of metabolism; metabolic syndromes; stroke; Alzheimer's disease; schizophrenia; autism; stress and anxiety; innate Immune response

 **Bruno Chrcanovic** ([https://sciprofiles.com/profile/933906?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/933906?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://mau.se/en/persons/bruno.chrcanovic/>)

**Editorial Board Member**

Department of Prosthodontics, Faculty of Odontology, Malmö University, 211 19 Malmö, Sweden

**Interests:** implant dentistry; clinical research; oral rehabilitation; prosthodontics; oral surgery; oral pathology


 **Massimo Conese** ([https://sciprofiles.com/profile/205995?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/205995?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://sites.google.com/a/unifg.it/massimoconese/>)

**Editorial Board Member**

Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy

**Interests:** amniotic membrane-derived mesenchymal stem cells; adipose-derived mesenchymal stem cells; pathophysiology and therapy of cystic fibrosis; wound healing; dermal regeneration; interaction of drug delivery systems with cells; Parkinson's disease; neuroinflammation

**Special Issues, Collections and Topics in MDPI journals**

 **Di Gioia** ([https://sciprofiles.com/profile/736042?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/736042?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://www.unifg.it/it/rubrica/sante-di-gioia>)

**Editorial Board Member**

Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy

**Interests:** gene therapy of cystic fibrosis; cellular therapy of cystic fibrosis; CFTR "interactome"; pathophysiology of cystic fibrosis lung disease


**Special Issues, Collections and Topics in MDPI journals**

 **Elizabeth Disbrow**  
<https://www.lsuhs.edu/departments/school-of-medicine/neurology/faculty>)

**Editorial Board Member**

Department of Neurology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, USA

**Interests:** Parkinson's disease; Alzheimer's disease; neuropsychological and motor testing; functional brain imaging; human and non-human electrophysiological recording

 **Dragan M. Djuric** ([https://sciprofiles.com/profile/1477745?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/1477745?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
[https://www.researchgate.net/profile/Dragan\\_Djuric2](https://www.researchgate.net/profile/Dragan_Djuric2))

**Editorial Board Member**

Faculty of Medicine, The University of Belgrade, Belgrade, Serbia

**Interests:** experimental models of cardiometabolic diseases; clinical research; myocardial infarction; heart failure; diabetic and pre-diabetic cardiomyopathy; cardiovascular effects of hyperhomocysteinemia; hypermethioninemia; ischaemia-reperfusion aging; gasotransmitters; cardiovascular protection; innovative therapy


 **Pradeep K. Dudeja**  
<https://chicago.medicine.uic.edu/departments/academic-departments/medicine/gastroenterology-and-hepatology/people/name/pradeep-k-dudeja/>)

**Editorial Board Member**

1. Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA

2. Jesse Brown VA Medical Center, Medical Research Service (600/151), 820 South Damen Avenue, Chicago, IL 60612, USA

**Interests:** diarrhea; pathophysiology; intestinal transport; gut-microbe interactions; inflammatory bowel diseases; intestinal electrolyte absorption

 **Felicity Gavins** ([https://sciprofiles.com/profile/1266266?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/1266266?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://www.brunel.ac.uk/people/felicity-gavins>)

**Editorial Board Member**

Brunel University London, Uxbridge, UK

**Interests:** inflammation; thrombosis; ischaemia reperfusion injury; stroke; neutrophils; platelets; endothelial dysfunction; imaging; in vivo models of disease; translational medicine

 **Albert Gjedde**  
<https://www.researchgate.net/profile/Albert-Gjedde>)



**Editorial Board Member**

Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark



**Interests:** brain; energy; metabolism; neuroenergetics; monoaminergic neurotransmission; neuroscience



**Brian R. Harris** ([https://sciprofiles.com/profile/2456972?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/2456972?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://www.lsuhs.edu/departments/school-of-graduate-studies/molecular-and-cellular-physiology/research/harris-lab>  

Editorial Board Member

Louisiana State University Health Sciences Center, Shreveport, LA, USA

**Interests:** physiology and pathophysiology of the microcirculation; retinal microvascular complications of diabetes; retinal pathologies



**Vladimir Jakovljevic** ([https://sciprofiles.com/profile/230954?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/230954?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<http://www.medf.kg.ac.rs>

Editorial Board Member

Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

**Interests:** oxidative stress; cardiology; pharmacology; diabetes; apoptosis; internal medicine; hypertension; antioxidants; reactive oxygen species; rehabilitation

**Special Issues, Collections and Topics in MDPI journals**



**Mirosław Kornek** ([https://sciprofiles.com/profile/978308?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/978308?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://www.biotechpharmasummit.com/index.php/liquid-biopsy-2020-speakers/miroslaw-kornek/>

Editorial Board Member

Department of Internal Medicine I, University Bonn, Venusberg Campus 1, 53127 Bonn, Germany

**Interests:** hepatology; liver diseases; HCC; extracellular vesicles; exosomes; microvesicles

**Special Issues, Collections and Topics in MDPI journals**



**Igor Kosanovic** ([https://sciprofiles.com/profile/909502?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/909502?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://pvrinstitute.org/en/professionals/directory/member/4958>

Editorial Board Member

Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia

**Interests:** pulmonary hypertension; high-altitude medicine; lung fibrosis

**Special Issues, Collections and Topics in MDPI journals**



**Peter R. Kvietys** ([https://sciprofiles.com/profile/1617114?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/1617114?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://faculty.alfaisal.edu/pkvietys/biocv>

Editorial Board Member

College of Medicine, Alfaisal University, P.O. Box 50927, Riyadh 11533, Saudi Arabia

**Interests:** basic mechanisms of the inflammatory response; inflammatory pathologies; microcirculation; vascular biology; neutrophil-endothelial interactions; IBD and gastritis (gastrointestinal); ARDS (pulmonary); ischemia/reperfusion (heart)



**Lukas Margaritis** ([https://sciprofiles.com/profile/668756?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/668756?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<http://www.bioacademy.gr/faculty-details/HMmF/lukas>

Editorial Board Member

Faculty of Biology, University of Athens, Athens, Greece

**Interests:** transmission electron microscopy (TEM); computer reconstruction; lab animal handling and irradiation; neurobiology; cell; biophysics; radiation biology



**Osamu Matsuo** ([https://sciprofiles.com/profile/1322102?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/1322102?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
[https://www.researchgate.net/profile/Osamu\\_Matsuo](https://www.researchgate.net/profile/Osamu_Matsuo)

Editorial Board Member

Kindai University Faculty of Medicine, Osakasayama 589-8511, Japan

**Interests:** haemostasis; fibrinolysis; thrombolysis; acute myocardial infarction; thromboembolism; regeneration; medical education; coaching; communication

**Dr. Thivanka Muthumalage** ([https://sciprofiles.com/profile/1074998?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/1074998?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))

**Website** (<https://www.urmc.rochester.edu/education/graduate/phd/toxicology/faculty-trainees/postdoctoral-fellows.aspx>)

Editorial Board Member

Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA

**Interests:** vaping; electronic nicotine delivery systems; tobacco; unfolded protein response; X box binding protein 1; activating transcription factor 6



**Tadayuki Oshima** ([https://sciprofiles.com/profile/135311?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/135311?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://researchmap.jp/read0137243/?lang=english>

Editorial Board Member

Hyogo College of Medicine, Nishinomiya, Japan

**Interests:** endoscopic diagnosis and treatment of GI cancers; tight junction proteins related to inflammatory; GI disorders including esophagitis; gastritis; dyspepsia and inflammatory bowel diseases




**Gaetano Parrozzani** ([https://sciprofiles.com/profile/716710?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name](https://sciprofiles.com/profile/716710?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))  
<https://www.didattica.unipd.it/offerta/docente/92627821F0131D6ACAEDFE45AA22D317>

Editorial Board Member



Department of Neuroscience–Ophthalmology, University of Padova, Via Giustiniani 2, 35128 Padova, Italy

**Interests:** ocular and optic pathway oncology; retinal and optic pathway pathophysiology




 [Juhani Partanen \(https://sciprofiles.com/profile/2589997?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name\)](https://sciprofiles.com/profile/2589997?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)  
<https://www.researchgate.net/profile/Juhani-Partanen>

Editorial Board Member

 [\(toggle desktop layout cookie\)](#)  

HUS, Imaging Centre, Clinical Neurophysiology, Helsinki University and Helsinki University Hospital, Helsinki, Finland

**Interests:** needle electromyography; nerve conduction studies; reflex and late response (F-response) measurements; electric activity of muscle spindles

 [Jitka Pechánová \(https://sciprofiles.com/profile/81807?utm\\_source=mdpi.com&utm\\_medium=website&utm\\_campaign=avatar\\_name\)](https://sciprofiles.com/profile/81807?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)  
[https://www.sav.sk/?lang=en&doc=user-org-user&user\\_no=1493](https://www.sav.sk/?lang=en&doc=user-org-user&user_no=1493)

Editorial Board Member

Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia

**Interests:** nitric oxide; polyphenolic compounds; cardiovascular system; hypertension; metabolic syndrome

**[Special Issues, Collections and Topics in MDPI journals](#)**

Displaying Editorial board member 1-30 on page 1 of 2.

Go to page [1](#) [2](#) ([/journal/pathophysiology/editors?page\\_no=2](/journal/pathophysiology/editors?page_no=2)) > ([/journal/pathophysiology/editors?page\\_no=2](/journal/pathophysiology/editors?page_no=2))

**[Pathophysiology](#)** (</journal/pathophysiology>), EISSN 1873-149X, Published by MDPI

**[RSS](#)** (</rss/journal/pathophysiology>) **[Content Alert](#)** (</journal/pathophysiology/toc-alert>)

Further Information

**[Article Processing Charges](#)** ([/apc](#))

**[Pay an Invoice](#)** ([/about/payment](#))

**[Open Access Policy](#)** ([/openaccess](#))

**[Contact MDPI](#)** ([/about/contact](#))

**[Jobs at MDPI](#)** (<https://careers.mdpi.com>)

Guidelines

**[For Authors](#)** ([/authors](#))

**[For Reviewers](#)** ([/reviewers](#))

**[For Editors](#)** ([/editors](#))

**[For Librarians](#)** ([/librarians](#))

**[For Publishers](#)** ([/publishing\\_services](#))

**[For Societies](#)** ([/societies](#))

**[For Conference Organizers](#)** ([/conference\\_organizers](#))

MDPI Initiatives

**[Sciforum](#)** (<https://sciforum.net>)

**[MDPI Books](#)** (<https://www.mdpi.com/books>)

**[Preprints.org](#)** (<https://www.preprints.org>)

**[Scilit](#)** (<https://www.scilit.net>)

**[SciProfiles](#)** ([https://sciprofiles.com?utm\\_source=mdpi.com&utm\\_medium=bottom\\_menu&utm\\_campaign=initiative](https://sciprofiles.com?utm_source=mdpi.com&utm_medium=bottom_menu&utm_campaign=initiative))

**[Encyclopedia](#)** (<https://encyclopedia.pub>)

**[JAMS](#)** (<https://jams.pub>)

**[Proceedings Series](#)** ([/about/proceedings](#))

Follow MDPI


**[LinkedIn](https://www.linkedin.com/company/mdpi)** (<https://www.linkedin.com/company/mdpi>)

**[Facebook](https://www.facebook.com/MDPIOpenAccessPublishing)** (<https://www.facebook.com/MDPIOpenAccessPublishing>)

**[Twitter](https://twitter.com/MDPIOpenAccess)** (<https://twitter.com/MDPIOpenAccess>)



Subscribe to receive issue release notifications and newsletters from MDPI journals

Select options 

Enter your email address...

 Subscribe

Brief Report

# Random Blood Glucose, but Not HbA1c, Was Associated with Mortality in COVID-19 Patients with Type 2 Diabetes Mellitus—A Retrospective Study

Stefanus Gunawan Kandinata <sup>1</sup>, Soebagijo Adi Soelistijo <sup>2,\*</sup>, Agung Pranoto <sup>2</sup> and Erwin Astha Triyono <sup>3</sup>

<sup>1</sup> Department of Internal Medicine, Dr. Soetomo General Academic Hospital—Faculty of Medicine, Airlangga University, Surabaya 60132, Indonesia

<sup>2</sup> Endocrinology, Metabolism and Diabetes Unit, Department of Internal Medicine, Dr. Soetomo General Academic Hospital—Faculty of Medicine, Airlangga University, Surabaya 60132, Indonesia

<sup>3</sup> Tropical and Infectious Disease Unit, Department of Internal Medicine, Dr. Soetomo General Academic Hospital—Faculty of Medicine, Airlangga University, Surabaya 60132, Indonesia

\* Correspondence: soebagijo.adi.s@fk.unair.ac.id

**Abstract:** Previous studies have yielded inconsistent results on whether glycated hemoglobin (HbA1c) and random blood glucose (RBG) are associated with mortality of coronavirus disease 2019 (COVID-19) patients with type 2 diabetes mellitus (T2DM). This study aimed to assess the association of HbA1c and RBG with mortality among COVID-19 patients with T2DM. A retrospective study was conducted on 237 patients with COVID-19 and T2DM (survival ( $n = 169$ ) and non-survival groups ( $n = 68$ )). Data on socio-demography, comorbidities, clinical symptoms, laboratory examination, and mortality were collected. Patients in the non-survival group had an older age range as compared with those in the survival group (60 (52.3–65.0) vs. 56.0 (48.5–61.5) years,  $p = 0.009$ ). There was no statistical gender difference between the two groups. After matching was done, chronic kidney disease, NLR, d-dimer, procalcitonin, and random blood glucose were higher in the non-survival group compared to the survival group ( $p < 0.05$ ). HbA1c levels were similar in survivors and non-survivors (8.7% vs. 8.9%,  $p=0.549$ ). The level of RBG was independently associated with mortality of COVID-19 patients with T2DM ( $p = 0.003$ , adjusted OR per 1-SD increment 2.55, 95% CI: 1.36–4.76). In conclusion, RBG was associated with the mortality of COVID-19 patients with T2DM, but HbA1c was not.

**Keywords:** diabetes; HbA1c; mortality; random blood glucose; COVID-19



**Citation:** Kandinata, S.G.; Soelistijo, S.A.; Pranoto, A.; Triyono, E.A. Random Blood Glucose, but Not HbA1c, Was Associated with Mortality in COVID-19 Patients with Type 2 Diabetes Mellitus—A Retrospective Study. *Pathophysiology* **2023**, *30*, 136–143. <https://doi.org/10.3390/pathophysiology30020012>

Academic Editors: Jonathan Steven Alexander and Olga Pecháňová

Received: 24 November 2022

Revised: 5 March 2023

Accepted: 3 April 2023

Published: 6 April 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

The coronavirus disease 2019 (COVID-19) pandemic has caused over 6.5 million deaths [1,2]. Vaccination programs have been carried out worldwide, but they still encounter challenges in implementation [3]. It is imperative that studies are conducted to improve in-hospital treatments for vulnerable groups, including individuals with type 2 diabetes mellitus (T2DM) who have a higher risk of severe COVID-19 [4–6]. A study revealed that even with the absence of other comorbidities, diabetic patients had a higher risk of severe pneumonia, higher hypercoagulable state, higher levels of tissue injury-related enzymes, and uncontrolled inflammatory response [7]. SARS-CoV-2 infection in T2DM could cause severe disease and higher mortality because of some close interactions: (1) hyperglycemia state in T2DM patients could modulate inflammatory responses and therefore predispose them to severe COVID-19; (2) SARS-CoV-2 infection in T2DM individuals could increase the reactive oxygen species (ROS) and inflammatory cytokines such as interleukin 6 and interferon-gamma, which could increase the chance for acute lung damage and acute respiratory distress syndrome (ARDS); (3) SARS-CoV-2 infection in T2DM individuals could induce insulin resistance and thereby induce hyperglycemia and vascular endothelial damages, leading to disseminated intravascular coagulation, thromboembolism, or

cardiovascular events; and (4) in diabetic patients, ACE-2 receptors, receptors for SARS-CoV-2 entry into host cells, are more prevalent, causing higher SARS-CoV-2 and therefore increased severity of pneumonia [8].

T2DM, one of the three types of diabetes, is concerning because its prevalence has been forecasted to increase from 6059 cases per 100,000 in 2017 to 7079 cases per 100,000 in 2030 [9]. T2DM has been associated with insulin resistance, a compensatory state due to a continuous increase in insulin production [9]. Elevated insulin will cause obesity, which in turn leads to insulin resistance—making a continuous cycle until pancreatic beta-cells inadequately meet the insulin demand [9]. This condition results in long-term hyperglycemia that leads to diabetic complications: macrovascular (cardiovascular disease, peripheral artery disease, or stroke), microvascular (nephropathy, neuropathy, or retinopathy), or miscellaneous complications, such as thyroid dysfunction [9].

In diagnosing T2DM, glycated hemoglobin (HbA1c) and random blood glucose (RBG) are robust indicators [10,11]. A correlation between HbA1c and mortality and morbidity in T2DM patients has been reported previously [12,13]. A systematic review conducted to assess whether HbA1c and RBG are associated with mortality of COVID-19 patients with T2DM [14] yielded inconsistent results. Therefore, this study aims to investigate the role of HbA1c and RBG as the mortality risk factors for COVID-19 patients with T2DM in the Indonesian population. Furthermore, a study evaluating the association between HbA1C or RBG and mortality has never been done in Indonesia to this date to the best of our knowledge.

## 2. Materials and Methods

### 2.1. Study Design and Participants

In this retrospective study, patients with COVID-19 and T2DM ( $n = 348$ ), treated between October 2020 and March 2021 in Dr. Soetomo General Academic Hospital, Surabaya, Indonesia, were recruited. The inclusion criteria were: (1) adult patients ( $\geq 18$  years old); (2) having T2DM as confirmed by International Statistical Classification of Diseases version 2010 (ICD-10) criteria; (3) having COVID-19 as confirmed by nasal swab reverse transcription polymerase chain reaction (RT-PCR); and (4) undergoing hospitalization in the isolation room. Patients diagnosed with leukemia, hemoglobinopathy, thalassemia, iron deficiency anemia, and hemolytic anemia were excluded from the study. The study protocol was approved by the Ethical Committee of Health Research of Dr. Soetomo General Academic Hospital (No. 0460/LOE/301.4.2/V/2021—Approval date: 5 May 2021) following the guidance from the Office for Human Research Protections (OHRP), under the requirement of the U.S. Department of Health and Human Services (HHS).

### 2.2. Study Measures

We collected and assessed the data on sociodemographics, comorbidities, clinical symptoms, laboratory examinations, and the outcome of the patients. Sociodemographic data included age and sex. The comorbidities recorded were previous diabetes mellitus history, cardiovascular disease, cerebrovascular disease, chronic kidney disease, and hypertension. The clinical symptoms observed were breathing difficulty, fever, cough, sore throat, aches and pain, diarrhea, anosmia, headache, and nausea. We also obtained laboratory examination results including neutrophil-to-lymphocyte ratio (NLR), platelet, RBG, HbA1c, D-dimer, fibrinogen, C-reactive protein (CRP), procalcitonin, and ferritin. Random blood glucose was measured as venous plasma glucose in mg/dL. The laboratory examinations were obtained from the initial hospital admission.

The severity of COVID-19 was assessed based on WHO 2021 criteria [15]. The patients were divided into two groups based on outcomes during hospitalization (survival vs. non-survival). Both of these groups were matched for age, gender, and severity of COVID-19.

### 2.3. Statistical Analysis

Descriptive statistics were presented in frequency (n) and percentage (%) for categorical variables and in mean  $\pm$  SD for normally distributed continuous variables or median (interquartile range (IQR)) for skewed variables. Plausible associated factors with the outcome of COVID-19 patients with T2DM were determined using the  $\chi^2$  test or Fisher exact test for categorical variables and the independent *t*-test or Mann–Whitney U test for continuous variables. A *p*-value of  $<0.05$  was considered statistically significant. Significant results were followed by a logistic regression analysis to assess whether they were associated with mortality. The odds ratio (OR) and 95% confidence interval (CI) were calculated per 1-SD increment. All statistical analyses were performed on IBM SPSS Statistics 25.0 for Windows.

## 3. Results

### 3.1. Characteristics of Patients with COVID-19 and T2DM

There were 348 patients admitted to Dr. Soetomo General Academic Hospital during the study period. Of them, 237 were included in the study. The clinical characteristics of the study population are presented in Table 1. A total of 169 (71.3%) patients survived and 68 (28.7%) died. There was a significant difference between the age of those who survived and those who died (56 (48.5–61.5) years old vs. 60 (52.3–65.0) years old,  $p = 0.009$ ). No significant gender difference was found between the two groups ( $p = 0.140$ ). Severe cases and breathing difficulty were more prevalent in the deceased group compared to the survivors (77.9% vs. 62.1%,  $p = 0.020$ ; 82.4% vs. 62.8%,  $p = 0.026$ ).

**Table 1.** Characteristics of COVID-19 patients with T2DM (unmatched).

Variables	Category	Total (n = 237)	Survivors (n = 169, 71.3%)	Non-Survivors (n = 68, 28.7%)	<i>p</i> -Value
Age (years old), median (IQR)		56.0 (50.0–63.0)	56.0 (48.5–61.5)	60.0 (52.3–65.0)	0.009
Sex	Male	125 (52.7%)	84 (49.7%)	41 (60.3%)	0.140
	Female	112 (47.3%)	85 (50.3%)	27 (39.7%)	
Comorbidities	Cardiovascular diseases	25 (10.5%)	14 (8.3%)	11 (16.2%)	0.074
	Cerebrovascular disease	13 (5.5%)	7 (4.1%)	6 (8.8%)	0.204
	Chronic kidney disease	61 (25.7%)	31 (18.3%)	30 (44.1%)	$<0.001$
	Hypertension	116 (48.6%)	78 (46.2%)	38 (55.9%)	0.175
Initial symptom	Breathing difficulty	171 (72.2%)	115 (68.0%)	56 (82.4%)	0.026
	Fever	120 (50.6%)	83 (49.1%)	37 (54.4%)	0.460
	Cough	166 (70.0%)	122 (72.2%)	44 (64.7%)	0.255
	Sore throat	11 (4.6%)	8 (4.7%)	3 (4.4%)	1.000
	Aches and pains	9 (3.8%)	6 (3.6%)	3 (4.4%)	0.719
	Weak body	36 (15.2%)	23 (13.6%)	13 (19.1%)	0.285
	Diarrhea	22 (9.3%)	18 (10.7%)	4 (5.9%)	0.253
	Anosmia	15 (6.3%)	10 (5.9%)	5 (7.4%)	0.769
	Headache	1 (0.4%)	1 (0.6%)	0 (0%)	1.000
Nausea	36 (15.2%)	29 (17.2%)	7 (10.3%)	0.183	
Disease severity	Non-severe	79 (33.3%)	64 (37.9%)	15 (22.1%)	0.020
	Severe	158 (66.7%)	105 (62.1%)	53 (77.9%)	

After matching for age, gender, and case severity, the non-survival group had more chronic kidney disease than the survival group (30 (44.1%) vs. 18 (26.5%),  $p = 0.031$ ). A significant difference between the two groups was not observed in other comorbidities (Table 2).

**Table 2.** Risk factors associated with mortality of COVID-19 patients with T2DM (matched).

Variable	Category	Total (n = 136)	Survivors (n = 68)	Non-Survivors (n = 68)	p-Value
Comorbidity	Cardiovascular	20 (14.7%)	9 (13.2%)	11 (16.2%)	0.628
	Cerebrovascular	7 (5.1%)	1 (1.5%)	6 (8.8%)	0.052
	Chronic kidney disease	48 (35.3%)	18 (26.5%)	30 (44.1%)	0.031
	Hypertension	71 (52.2%)	33 (48.5%)	38 (55.9%)	0.391
Laboratory parameter	NLR	7.2 (5.0–12.4)	6.0 (4.1–9.6)	9.1 (5.9–15.0)	0.001
	Platelet, $\times 10^3/\mu\text{L}$	229.5 (190.0–305.3)	229.0 (191.0–299.0)	228.0 (179.0–284.0)	0.913
	D-dimer, ng/mL	1310.0 (770.0–3780.0)	870.0 (500.0–2120.0)	2225.0 (1080.0–14,270.0)	<0.001
	Fibrinogen, mg/dL	520.9 $\pm$ 180.1	543.5 $\pm$ 157.2	494.3 $\pm$ 202.2	0.038
	CRP, mg/dL	7.9 (3.7–13.8)	6.9 (3.1–11.6)	8.9 (5.8–14.1)	0.165
	Procalcitonin, ng/mL	0.3 (0.1–0.5)	0.2 (0.1–0.3)	0.4 (0.2–1.0)	<0.001
	Ferritin, ng/mL	1014.8 (574.0–1716.4)	886.9 (492.0–1511.7)	1080.2 (629.2–2167.5)	0.103
	Random blood glucose, mg/dL	218.5 (150.8–323.8)	206.0 (126.0–289.5)	243.5 (177.0–375.5)	0.002
	HbA1c, %	8.8 (7.0–11.5)	8.7 (7.4–11.6)	8.9 (6.9–11.5)	0.549

In regard to the laboratory parameters, the non-survival group had a significantly higher level of NLR (9.1 (5.9–15.0) vs. 6.0 (4.1–9.6),  $p = 0.001$ ), d-dimer (2225 (1080–14,270) vs. 870 (500–2,120),  $p < 0.001$ ), and procalcitonin (0.4 (0.2–1.0) vs. 0.2 (0.1–0.3),  $p < 0.001$ ) (Table 2). In contrast, the survival group showed significantly higher fibrinogen levels than the deceased group (543.5  $\pm$  157.2 vs. 494.3  $\pm$  202.2,  $p = 0.038$ ) (Table 2).

### 3.2. Association of HbA1c Level with Mortality of COVID-19 Patients with T2DM

The results of the analysis of HbA1c level as a mortality predictor in COVID-19 patients with T2DM is shown in Table 2. HbA1c value was similar in survivors and non-survivors (8.7% (7.4–11.6) vs. 8.9% (6.9–11.5),  $p = 0.549$ ).

### 3.3. Association of Random Blood Glucose with Mortality of COVID-19 Patients with T2DM

There was a significant difference between survivors and non-survivors (206.0 (126.0–289.5) mg/dL vs. 243.5 (177.0–375.5) mg/dL,  $p = 0.002$ ) (Table 2).

In the univariate logistic regression analysis, a higher RBG level was associated with a higher risk of mortality (OR 2.05, 95% CI 1.40–3.68,  $p = 0.002$ ). After adjustment for potential confounders, the association between RBG and mortality remained significant (adjusted OR per 1-SD increment 2.55, 95% CI: 1.36–4.76,  $p = 0.003$ ) (Table 3).

**Table 3.** Multivariate regression analysis of factors associated with mortality.

Model	Per 1-SD Increment	
	OR (95% CI)	p-Value
Random blood glucose, crude	2.05 (1.40–3.68)	0.002
Model 1	2.16 (1.30–3.58)	0.003
Model 2	2.08 (1.24–3.50)	0.006
Model 3	2.32 (1.33–4.03)	0.003
Model 4	2.37 (1.33–4.21)	0.003
Model 5	2.79 (1.51–5.17)	0.001
Model 6	2.55 (1.38–4.71)	0.003

Table 3. Cont.

Model	Per 1-SD Increment	
	OR (95% CI)	p-Value
Model 7	2.55 (1.37–4.73)	0.003
Model 8	2.55 (1.36–4.76)	0.003

Logistic regression analyses were performed to assess the association between RBG with in-hospital mortality of COVID-19 with T2DM. Multivariable-adjusted model 1 included adjustment for d-dimer; model 2 adjusted for variables in model 1 and procalcitonin; model 3 adjusted for variables in model 2 and NLR; model 4 adjusted for variables in model 3 and chronic kidney disease; model 5 adjusted for variables in model 4 and fibrinogen; model 6 adjusted for variables in model 5 and ferritin; model 7 adjusted for variables in model 6 and CRP; and Model 8 adjusted for variables in model 7 and cerebrovascular disease.

#### 4. Discussion

This present study was conducted to determine the association of HbA1c and RBG with the mortality of COVID-19 patients with T2DM. During our initial analysis, we found that age was associated with the mortality of COVID-19 patients with T2DM. Previous studies have also revealed that age is one of the mortality-determining factors in COVID-19 and T2DM patients [13,16]. Although some studies found an association between sex and the mortality of COVID-19 cases with T2DM, the findings were not consistent [16,17]. A study found that among COVID-19 patients who had T2DM and cardiovascular disease, sex was not associated with in-hospital mortality [18]. In this present study, sex was also not associated with COVID-19 outcomes. In addition, among the comorbidities in the COVID-19 and T2DM patients (cardiovascular diseases, cerebrovascular diseases, chronic kidney diseases, and hypertension), we only found an association between chronic kidney disease and mortality. This finding is in agreement with two previous studies that found that COVID-19 patients with T2DM and kidney diseases had a significantly higher chance of death [16,19]. T2DM patients with diabetic nephropathy show chronic systemic inflammation that contributes to immunosuppression, which determines morbidity and mortality [20].

We found that breathing difficulty was significantly associated with mortality. A retrospective study in Wuhan, where a total of 153 patients were included, found a similar result [21]. Furthermore, some laboratory indicators such as NLR, d-dimer, and procalcitonin levels were associated with the mortality of patients. Several previous studies have also reported similar findings, including those conducted in China [21–23] and Iran [18], reflecting a more significant inflammatory response, hypercoagulable state, endothelial injury, and coinfection in the deceased group. However, we noted that the fibrinogen level was lower in the non-survivor group. This finding was similar to the CORONADO study, which observed slightly lower fibrinogen levels in the deceased group [24]. Furthermore, a study by Guo [7] found no statistically significant differences regarding fibrinogen levels in diabetic and non-diabetic patients infected with COVID-19. A considerable amount of fibrinogen data (26.5%) was found to be missing in the non-survivors, which is also thought to have influenced the results.

We found that HbA1c level was not statistically significant with mortality, suggesting it is not a predictor of mortality, which aligns with previous studies in France [24] and Austria [25]. One of the reasons for this is that there is no association between HbA1c level and COVID-19 severity, as reported by a previous study [26]. In addition, HbA1c as a mortality predictor is probably not significant because of its involvement in multiple factors, including roles in low-grade inflammation and immune cell functions, which are affected during SARS-CoV-2 infection [14]. In a previous study, the HbA1c level had statistical significance as a mortality prediction among COVID-19 and T2DM population only after the following classification was made: <7%, 7–8%, 8–9% and >9% [21]. We were unable to classify the HbA1c level based on this classification.

RBG level, however, was an independent risk factor for mortality in this present study. This finding is in agreement with that reported by a study carried out in Wuhan, China [21]. The level of capillary blood glucose on admission was found to be an independent mor-

tality risk factor among COVID-19 patients with T2DM [27]. There are some possible explanations of how RBG could be an independent risk factor for COVID-19 mortality in T2DM individuals: (1) high blood glucose in T2DM patients could modulate inflammatory responses leading to severe COVID-19 and predispose cytokine storm-associated death [8]; (2) increased glucose level could promote the replication of SARS-CoV-2 via mitochondrial ROS and hypoxia-inducible factor 1- $\alpha$  [28]; (3) high blood glucose might cause glucotoxicity that could lead to interstitial lung damage and therefore increase the risk of ARDS and death [8]; and (4) elevated blood glucose could also cause endothelial damage, which is associated with a risk of thromboembolic events such as pulmonary embolism [8]. Hence, blood glucose management during hospitalization is critical, as was suggested in a previous report [21]. Other than the in-hospital treatments, glycemic control could be achieved by improving patients' social support, self-efficacy, and self-care activities [29].

Despite the aforementioned literature in support of the findings of this present study, those who reported otherwise are worth noting. A study of 1004 diabetic patients with COVID-19 found that HbA1c or RBG was statistically associated with mortality [30]. Another study involving 3,295 COVID-19 patients found that HbA1c was associated with severe COVID-19, ICU admission, or all-cause mortality in both diabetic and non-diabetic groups [31]. A meta-analysis of nine trials concluded that a higher level of HbA1c was a parameter for higher mortality risk among COVID-19 and T2DM patients [32].

With the current number of samples used in this study, we have a limitation in classifying the ranges of HbA1c levels. Moreover, the HbA1c and RBG levels were only measured upon admission, whilst the progress of diabetes and the alteration of glycemic status during the hospitalization were not measured in this study.

## 5. Conclusions

HbA1c level had no association with mortality of COVID-19 patients with T2DM. In contrast, RBG level was an independent risk factor of mortality among individuals with SARS-CoV-2 infection and T2DM. Therefore, RBG level needs to be measured as early as possible in COVID-19-confirmed individuals with T2DM to establish early management to prevent mortality. For future studies, we suggest including a higher number of patients which could allow for a more specific classification of HbA1c level ranges.

**Author Contributions:** Conceptualization: S.G.K. and S.A.S.; methodology: S.G.K., S.A.S., A.P., and E.A.T.; software: S.G.K.; validation: S.A.S., A.P., and E.A.T.; formal analysis: S.G.K., S.A.S., A.P., and E.A.T.; investigation: S.A.S. and A.P.; resources: E.A.T.; data curation: S.G.K., S.A.S., A.P., and E.A.T.; writing—original data preparation: S.G.K. and S.A.S.; writing—review and editing: A.P. and E.A.T.; visualization: S.G.K.; supervision: S.A.S., A.P., and E.A.T.; project administration: S.G.K. and S.A.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study protocol was approved by the Ethical Committee of Health Research of Dr. Soetomo Hospital (No. 0460/LOE/301.4.2/V/2021—5 May 2021).

**Informed Consent Statement:** Written informed consent to publish this paper has been obtained from the patients.

**Data Availability Statement:** On behalf of future research, the raw data can be accessed by contacting the corresponding author.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Sukartini, T.; Rosyid, A.N.; Revita, N.C.T.; Aini, H.N. The effectiveness of pulmonary rehabilitation on pulmonary function among adults patients of COVID-19 survivors: A systematic review. *J. Respirasi* **2022**, *8*, 15–25.
2. Suryantoro, S.D.; Thaha, M.; Hayati, M.R.; Yusuf, M.; Pikir, B.S.; Susilo, H. Correlation between anti-hypertensive drugs and disease progression among moderate, severe, and critically ill COVID-19 patients in the second referral hospital in Surabaya: A retrospective cohort study. *F1000Research* **2021**, *10*, 1–20. [[CrossRef](#)] [[PubMed](#)]



3. Rosiello, D.F.; Anwar, S.; Yufika, A.; Adam, R.Y.; Ismaeil, M.I.; Ismail, A.Y.; Dahman, N.B.; Hafsi, M.; Ferjani, M.; Sami, F.S.; et al. Acceptance of COVID-19 vaccination at different hypothetical efficacy and safety levels in ten countries in Asia, Africa, and South America. *Narra J.* **2021**, *1*, 3. [CrossRef]
4. Mudatsir, J.K.F.; Wulandari, L.; Soegiarto, G.; Purnamasari, Y.; Mahdi, B.A. Predictors of COVID-19 severity: A systematic review and meta-analysis. *F1000Research* **2020**, *9*, 1107. [CrossRef]
5. Singh, A.K.; Singh, R. Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19? *Diabetes Metab. Syndr. Clin. Res. Rev.* **2020**, *14*, 725–727. [CrossRef]
6. Fang, L.; Karakiulakis, G.; Roth, M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir. Med.* **2020**, *8*, e21. [CrossRef]
7. Guo, W.; Li, M.; Dong, Y.; Zhou, H.; Zhang, Z.; Tian, C.; Qin, R.; Wang, H.; Shen, Y.; Du, K.; et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes Metab. Res. Rev.* **2020**, *36*, 1–9. [CrossRef]
8. Haryati, H.; Isa, M.; Assagaf, A.; Nurrasyidah, I.; Kusumawardhani, E. Clinical Characteristics of Hospitalized Individuals Dying with COVID-19 in Ulin Regional Hospital Banjarmasin. *J. Respirasi* **2021**, *7*, 1–7. [CrossRef]
9. Khan, M.A.B.; Hashim, M.J.; King, J.K.; Govender, R.D.; Mustafa, H.; Al Kaabi, J. Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. *J. Epidemiol. Glob. Health* **2020**, *10*, 107. [CrossRef]
10. Bekele, B.B.; Negash, S.; Bogale, B.; Tesfaye, M.; Getachew, D.; Weldekidan, F.; Balcha, B. Effect of diabetes self-management education (DSME) on glycated hemoglobin (HbA1c) level among patients with T2DM: Systematic review and meta-analysis of randomized controlled trials. *Diabetes Metab. Syndr. Clin. Res. Rev.* **2021**, *15*, 177–185. [CrossRef]
11. Bowen, M.E.; Xuan, L.; Lingvay, I.; Halm, E.A. Random blood glucose: A robust risk factor for type 2 diabetes. *J. Clin. Endocrinol. Metab.* **2015**, *100*, 1503–1510. [CrossRef]
12. Chiang, J.I.; Hanlon, P.; Li, T.C.; Jani, B.D.; Manski-Nankervis, J.A.; Furler, J.; Lin, C.C.; Yang, S.Y.; Nicholl, B.I.; Thuraisingam, S.; et al. Multimorbidity, mortality, and HbA1c in type 2 diabetes: A cohort study with UK and Taiwanese cohorts. *PLoS Med.* **2020**, *17*, e1003094. [CrossRef]
13. Wan, E.Y.F.; Yu, E.Y.T.; Chin, W.Y.; Ng, F.T.Y.; Chia, S.M.C.; Wong, I.C.K.; Chan, E.W.Y.; Lam, C.L.K. Age-specific associations of glycated haemoglobin variability with cardiovascular disease and mortality in patients with type 2 diabetes mellitus: A 10-year cohort study. *Diabetes Obes. Metab.* **2020**, *22*, 1316–1327. [CrossRef]
14. Prattichizzo, F.; de Candia, P.; Nicolucci, A.; Ceriello, A. Elevated HbA1c levels in pre-COVID-19 infection increases the risk of mortality: A systematic review and meta-analysis. *Diabetes Metab. Res. Rev.* **2022**, *38*, e3476. [CrossRef]
15. World Health Organization (WHO). Living Guidance for Clinical Management of COVID-19. 2021. Available online: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1> (accessed on 20 October 2022).
16. Al-Ozairi, E.; Brown, R.; Hamdan, Y.; Alabdullah, L.; Voase, N.; Al Kandari, J.; Alsaeed, D.; Al Ozairi, A.; Hasan, A.; Al-Mulla, F.; et al. Risk of mortality among inpatients with COVID-19 and type 2 diabetes: National data from Kuwait. *Endocrinol. Diabetes Metab.* **2021**, *4*, e00287. [CrossRef]
17. Biswas, M.; Rahaman, S.; Biswas, T.K.; Haque, Z.; Ibrahim, B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. *Intervirology* **2021**, *64*, 36–47. [CrossRef]
18. Rastad, H.; Karim, H.; Ejtahed, H.S.; Tajbakhsh, R.; Noorisepehr, M.; Babaei, M.; Azimzadeh, M.; Soleimani, A.; Inanloo, S.H.; Shafiabadi Hassani, N.; et al. Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease. *Diabetol. Metab. Syndr.* **2020**, *12*, 57. [CrossRef]
19. Leon-Abarca, J.A.; Memon, R.S.; Rehan, B.; Iftikhar, M.; Chatterjee, A. The impact of COVID-19 in diabetic kidney disease and chronic kidney disease: A population-based study. *Acta Biomed.* **2020**, *91*, e2020161.
20. D'Marco, L.; Puchades, M.J.; Romero-Parra, M.; Gorriz, J.L. Diabetic Kidney Disease and COVID-19: The Crash of Two Pandemics. *Front. Med.* **2020**, *7*, 199. [CrossRef]
21. Shi, Q.; Zhang, X.; Jiang, F.; Zhang, X.; Hu, N.; Bimu, C.; Feng, J.; Yan, S.; Guan, Y.; Xu, D.; et al. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients with Diabetes in Wuhan, China: A Two-Center, Retrospective Study. *Diabetes Care* **2020**, *43*, 1382–1391. [CrossRef]
22. Liu, Y.; Lu, R.; Wang, J.; Cheng, Q.; Zhang, R.; Zhang, S.; Le, Y.; Wang, H.; Xiao, W.; Gao, H.; et al. Diabetes, even newly defined by HbA1c testing, is associated with an increased risk of in-hospital death in adults with COVID-19. *BMC Endocr. Disord.* **2021**, *21*, 56. [CrossRef] [PubMed]
23. Hui, Y.; Li, Y.; Tong, X.; Wang, Z.; Mao, X.; Huang, L.; Zhang, D. The risk factors for mortality of diabetic patients with severe COVID-19: A retrospective study of 167 severe COVID-19 cases in Wuhan. *PLoS ONE* **2021**, *15*, e0243602. [CrossRef] [PubMed]
24. Wargny, M.; Potier, L.; Gourdy, P.; Pichelin, M.; Amadou, C.; Benhamou, P.Y.; Bonnet, J.B.; Bordier, L.; Bourron, O.; Chaumeil, C.; et al. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: Updated results from the nationwide CORONADO study. *Diabetologia* **2021**, *64*, 778–794. [CrossRef] [PubMed]
25. Sourij, H.; Aziz, F.; Bräuer, A.; Ciardi, C.; Clodi, M.; Fasching, P.; Karolyi, M.; Kautzky-Willer, A.; Klammer, C.; Malle, O.; et al. COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission. *Diabetes Obes. Metab.* **2021**, *23*, 589–598. [CrossRef] [PubMed]
26. Raoufi, M.; Khalili, S.; Mansouri, M.; Mahdavi, A.; Khalili, N. Well-controlled vs poorly-controlled diabetes in patients with COVID-19: Are there any differences in outcomes and imaging findings? *Diabetes Res. Clin. Pract.* **2020**, *166*, 108286. [CrossRef]

27. Chaudhuri, S.R.; Majumder, A.; Sanyal, D.; Biswas, A.; Bhattacharjee, K. Admission Blood Glucose but Not HbA1c Predicts Mortality in People with Diabetes Hospitalized with COVID-19 Infection. *Diabetes* **2021**, *70*, 1098. [[CrossRef](#)]
28. Lim, S.; Bae, J.H.; Kwon, H.S.; Nauck, M.A. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. *Nat. Rev. Endocrinol.* **2021**, *17*, 11–30. [[CrossRef](#)]
29. Paulsamy, P.; Ashraf, R.; Alshahrani, S.H.; Periannan, K.; Qureshi, A.A.; Venkatesan, K.; Manoharan, V.; Govindasamy, N.; Prabahar, K.; Arumugam, T.; et al. Social Support, Self-Care Behaviour and Self-Efficacy in Patients with Type 2 Diabetes during the COVID-19 Pandemic: A Cross-Sectional Study. *Healthcare* **2021**, *9*, 1607. [[CrossRef](#)]
30. Llanera, D.K.; Wilmington, R.; Shoo, H.; Lisboa, P.; Jarman, I.; Wong, S.; Nizza, J.; Sharma, D.; Kalathil, D.; Rajeev, S.; et al. Clinical characteristics of COVID-19 patients in a regional population with diabetes mellitus: The ACCREDIT study. *Front. Endocrinol.* **2021**, *12*, 1897. [[CrossRef](#)]
31. Alhakak, A.; Butt, J.H.; Gerds, T.A.; Fosbøl, E.L.; Mogensen, U.M.; Krøll, J.; Pallisgaard, J.L.; Gislason, G.H.; Torp-Pedersen, C.; Køber, L.; et al. Glycated haemoglobin levels among 3295 hospitalized COVID-19 patients, with and without diabetes, and risk of severe infection, admission to an intensive care unit and all-cause mortality. *Diabetes Obes. Metab.* **2022**, *24*, 499–510. [[CrossRef](#)]
32. Zhu, Z.; Mao, Y.; Chen, G. Predictive value of HbA1c for in-hospital adverse prognosis in COVID-19: A systematic review and meta-analysis. *Prim. Care Diabetes* **2021**, *15*, 910–917. [[CrossRef](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.